A Phase 1 interventional study of Pregabalin (Lyrica) and Placebo in Nerve Pain, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 5 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-02-09.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing pregabalin in Neuralgia — 4 open to participants now, 4 under way, 1 of them phase 3. Pregabalin · Neuralgia.
Among the 50 studies testing pregabalin in Neuralgia, this one is the 45th largest by enrollment, is one of 4 that started in 2008, is one of 3 in phase 1, and was the 13th registered.
1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.
Browse Neuralgia studies →4 of the 50 studies testing pregabalin in Neuralgia are open now, in 4 countries. Recruiting first, the newest first:
Moumtzidou Maria Aikaterini · Sites in Greece
Ages 18+ · Women only
Brainfarma Industria Química e Farmacêutica S/A · Sites in Brazil
Ages 18–75
Haisco Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–75
Helsinki University Central Hospital · Sites in Finland
Ages 18–75
By country, each count listing its studies:
Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 154 Neuralgia studies recruiting now, 78 (51%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 19 · Phase 4 12
First in 2002; this study’s year is marked. 4 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 52 across 833 interventional studies indexed under Neuralgia.
Median enrollment 109 across the 50 interventional studies. Of the 35 that completed or were terminated, 10 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 50 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
25 studies in Neuralgia by Viatris Inc.: none open now, none under way, none of them phase 3. Of 23 finished, 17 (74%) have results posted.
Among the 25 studies in Neuralgia by Viatris Inc., this one is the 11th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2008, is the only one in phase 1, and was the 10th registered.
Viatris Inc.’s Neuralgia studies by the year they started, since 2004.
2 of the studies testing pregabalin in Neuralgia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07712913Phase 3Brainfarma Industria Química e Farmacêutica S/AExtended-release Pregabalin for the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy and Postherpetic Neuralgia | 2027-06-01 |
| NCT07880223Moumtzidou Maria AikateriniComparison of Two Postoperative Care Strategies After Breast Surgery | 2027-08 |
Add all 2 to your calendar (.ics) → With an account.
Among the 50 studies testing pregabalin in Neuralgia, from their registry updates:
Among Viatris Inc.’s 25 in Neuralgia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess whether a cross-over type study design in post-traumatic neuropathic patients can be used to assess the activity of potential analgesic agents
Methodology study to evaluate a cross-over study design in post-traumatic neuropathic pain patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pregabalin (Lyrica)
Drug: Placebo
Oral, 75mg or 150mg capsules, BID
Oral, matched capsules, BID
Change From Baseline to Treatment Week 2 in Daily Pain Rating Scale
Daily Pain Rating Scale by treatment and sequence using an 11-point Likert scale: range 0 (no pain) to 10 (worst possible pain) over the past 24 hours. Self-assessment was performed daily on rising from bed (for the final time in the case of interrupted sleep). Average daily pain score: mean of the previous 7 days daily pain scores. Baseline was defined as the mean of the last 7 pre-treatment pain scores for each period. End of treatment was defined as the mean of the last 7 on treatment pain scores for each period.
Time frame: Week 0 to Week 2, Week 4 to Week 6 (Baseline to Week 2 [End of Treatment] for each treatment period)
Neuropathic Pain Symptom Inventory (NPSI)
NPSI at end of treatment: 10-item self-administered questionnaire assessing 5 dimensions of pain (burning superficial spontaneous pain, pressing deep spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dysesthesia). Each item consists of a question about the specific qualities of pain and an 11-point numerical scale range: 0 (absence of pain) to 10 (maximum intensity imaginable), and 2 temporal items related to spontaneous and paroxysmal pain. Maximum total score possible = 100.
Time frame: Week 0 to Week 2, Week 4 to Week 6 (Baseline to End of Treatment in Treatment Periods 1 and 2)
Subject Activity as Captured by the Actiwatch Score Device: Total Activity Score at End of Treatment
Total activity score: Day (8 am to 8 pm) at end of treatment. Accelerometer measured physical activity by monitoring degree and intensity of body motion. Data is reported as activity counts. Subject activity was collected hourly for the variables: peak, average, and total activity. Higher score indicates greater activity (no activity = 0; total possible score was not defined).
Time frame: Week 0 to Week 2, Week 4 to Week 6 (Baseline to End of Treatment in Treatment Periods 1 and 2)
Subjects participated in the study between 05 May 2008 and 10 February 2009.
| Milestone | Pregabalin First Then Placebo | Placebo First Then Pregabalin |
|---|---|---|
| Started | 13 | 12 |
| Received study treatment | 12 | 12 |
| Completed | 12 | 11 |
| Not completed | 1 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Intolerable pain level | 1 | 0 |
| Milestone | Pregabalin First Then Placebo | Placebo First Then Pregabalin |
|---|---|---|
| Started | 12 | 11 |
| Completed | 12 | 11 |
| Not completed | 0 | 0 |
| Milestone | Pregabalin First Then Placebo | Placebo First Then Pregabalin |
|---|---|---|
| Started | 12 | 11 |
| Completed | 12 | 11 |
| Not completed | 0 | 0 |
Daily Pain Rating Scale by treatment and sequence using an 11-point Likert scale: range 0 (no pain) to 10 (worst possible pain) over the past 24 hours. Self-assessment was performed daily on rising from bed (for the final time in the case of interrupted sleep). Average daily pain score: mean of the previous 7 days daily pain scores. Baseline was defined as the mean of the last 7 pre-treatment pain scores for each period. End of treatment was defined as the mean of the last 7 on treatment pain scores for each period.
| scores on scale | Period 1: Pregabalin | Period 1: Placebo | Period 2: Placebo | Period 2: Pregabalin |
|---|---|---|---|---|
| Baseline | 6.03 ± 1.29 | 5.24 ± 2.03 | 5.96 ± 0.88 | 5.31 ± 1.82 |
| Treatment Week 2 | 5.40 ± 1.34 | 5.08 ± 2.05 | 6.11 ± 1.20 | 4.38 ± 2.02 |
| Change from Baseline | -0.63 ± 1.01 | -0.16 ± 0.97 | 0.16 ± 1.07 | -0.93 ± 1.24 |
NPSI at end of treatment: 10-item self-administered questionnaire assessing 5 dimensions of pain (burning superficial spontaneous pain, pressing deep spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dysesthesia). Each item consists of a question about the specific qualities of pain and an 11-point numerical scale range: 0 (absence of pain) to 10 (maximum intensity imaginable), and 2 temporal items related to spontaneous and paroxysmal pain. Maximum total score possible = 100.
| scores on scale | Pregabalin/Placebo | Placebo/Pregabalin |
|---|---|---|
| Week 0 (Baseline: Treatment Period 1) | 5.31 ± 3.50 | 5.25 ± 2.38 |
| Week 2 (End of Treatment: Treatment Period 1) | 5.31 ± 3.30 | 4.91 ± 2.30 |
| Week 4 (Baseline: Treatment Period 2) | 4.33 ± 3.14 | 5.27 ± 2.45 |
| Week 6 (End of Treatment: Treatment Period 2) | 4.75 ± 3.39 | 3.00 ± 2.24 |
Total activity score: Day (8 am to 8 pm) at end of treatment. Accelerometer measured physical activity by monitoring degree and intensity of body motion. Data is reported as activity counts. Subject activity was collected hourly for the variables: peak, average, and total activity. Higher score indicates greater activity (no activity = 0; total possible score was not defined).
| scores on scale | Pregabalin | Placebo |
|---|---|---|
| Subject Activity as Captured by the Actiwatch Score Device: Total Activity Score at End of Treatment | 300000 ± 12000 | 270000 ± 12000 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pregabalin | — | 0/24 (0%) | 11/24 (45.8%) |
| Placebo | — | 0/24 (0%) | 10/24 (41.7%) |
| Event | Pregabalin | Placebo |
|---|---|---|
| DizzinessNervous system disorders | 6/24 | 1/24 |
| NauseaGastrointestinal disorders | 4/24 | 3/24 |
| HeadacheNervous system disorders | 3/24 | 0/24 |
| SomnolenceNervous system disorders | 3/24 | 0/24 |
| Dry mouthGastrointestinal disorders | 2/24 | 1/24 |
| FatigueGeneral disorders | 2/24 | 1/24 |
| VertigoEar and labyrinth disorders | 0/24 | 1/24 |
| Eye disorderEye disorders | 1/24 | 0/24 |
| Vision blurredEye disorders | 1/24 | 1/24 |
| Abdominal painGastrointestinal disorders | 0/24 | 1/24 |
| Age, Customized(years) | Pregabalin Then Placebo | Placebo Then Pregabalin | Total |
|---|---|---|---|
| 18 - 44 years | 4 ± 0 | 3 ± 0 | 7 ± 0 |
| 45 - 64 years | 5 ± 16.7 | 8 ± 11.8 | 13 |
| >=65 years | 4 ± 0 | 1 ± 0 | 5 ± 0 |
| Sex: Female, Male(Participants) | Pregabalin Then Placebo | Placebo Then Pregabalin | Total |
|---|---|---|---|
| Female | 7 | 7 | 14 |
| Male | 6 | 5 | 11 |
The record gives a start of May 2008, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2010, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pregabalin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →